Adicet Bio, Inc.
Adicet Bio discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Lead product candidate ADI-001 targets CD20 in Phase I trial for autoimmune diseases and lymphoma. Company also developing ADI-270 for renal cell carcinoma and other solid tumors/hematological malignancies. Founded in 2014, based in Boston, MA.
Overview
Strengths
- Consistent growth: revenue has compounded at 192.9% a year over 3 years, rising in 2 of them.
Weaknesses
- No sign of a competitive advantage: return on invested capital (latest 0.0%) has been below its cost of capital of 18.3% in each of the last 6 years.
- Operating profit does not cover interest expense.
- Our discounted cash flow model finds no value to support the current price: operating profit does not cover interest expense.
- Shareholder dilution: the share count has grown by 52.8% a year over the last three years.
- Currently loss-making: the latest fiscal year closed with a net loss.
- Unreliable cash generation: free cash flow was negative in 7 of the last 7 years.
Key Financial Data